The effects of empagliflozin on CKD progression and cardiovascular outcomes in EMPA-KIDNEY were quantitatively similar to effects reported in other SGLT2i trials1,23 and its effects on QALYs and healthcare costs, reported here, are likely generalizable to other SGLT2 inhibitors. Here, SLC5A2 is linked to chronic kidney disease.